Dogecoin Cash, Inc. (DOGP) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $2.13M is the value of all shares combined. Beta 2.78: the stock has moved about 178% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerDogecoin Cash, Inc. (DOGP) trades at $0.0131. Dogecoin Cash, Inc. operates in the telemedicine and cannabis industries, providing online referral services for medical marijuana cards. Market cap: $2.13M, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for DOGP: DOGP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DOGP against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
These figures come from statements filed 12 months ago — the most recent this company has published.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
DOGP: 1/2 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Dogecoin Cash, Inc. (DOGP) Healthcare & Pipeline Overview
Dogecoin Cash, Inc. focuses on telemedicine services for medical marijuana recommendations through its PrestoDoctor platform, targeting the cannabidiol and cannabis industries. The company develops related products like lozenges and topical creams, and intends to offer fashion apparel through its website, operating in a competitive and evolving regulatory landscape.
What Is the Investment Thesis for DOGP?
Dogecoin Cash, Inc. presents a high-risk, high-reward investment profile due to its focus on the evolving cannabis telemedicine market. The company's PrestoDoctor platform offers a direct-to-consumer approach for medical marijuana recommendations, potentially capitalizing on increasing acceptance and legalization trends. However, the company's negative P/E ratio of -1.65 and a profit margin of -195.0% indicate significant financial challenges. Growth catalysts include expanding PrestoDoctor's reach to new states and launching planned fashion apparel lines. Key risks involve regulatory hurdles, competition from established telemedicine providers, and the company's limited operating history. Investors should carefully consider the volatile nature of the cannabis industry and Dogecoin Cash, Inc.'s financial position before investing.
Based on FMP financials and quantitative analysis
DOGP Key Highlights
Market capitalization of $2.13M, indicating a micro-cap company with limited financial resources.
- P/E ratio of -1.65, reflecting net losses and potentially unsustainable operations.
- Gross margin of 63.4%, suggesting a strong ability to control production costs relative to revenue.
- Profit margin of -195.0%, indicating significant operational inefficiencies and high expenses.
- Beta of 2.78, indicating high volatility compared to the overall market.
Who Are DOGP's Competitors?
DOGP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CMPD CompuMed, Inc. | $6.80 | -0.29% | $8.77M | — |
| HLYK HealthLynked Corp. | $2.13 | 0.00% | $6.27M | — |
| MGRX Mangoceuticals, Inc. | $0.39 | +1.51% | $6.63M | — |
| BFRG Bullfrog AI Holdings, Inc. Common Stock | $0.48 | -1.98% | $8.82M | — |
| BBLN Babylon Holdings Limited | $0.55 | -13.99% | $14.1M | — |
| SCNX Scienture Holdings, Inc. | $0.35 | -2.69% | $14.1M | — |
| BEAT HeartBeam, Inc. | $0.40 | -2.14% | $22.3M | — |
| EUDA EUDA Health Holdings Limited | $13.12 | +0.15% | $24.5M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DOGP's Key Strengths?
Established PrestoDoctor platform for telemedicine consultations.
- Intellectual property license for medical marijuana edibles.
- Focus on the growing cannabis and telemedicine industries.
- Direct-to-consumer approach for medical marijuana recommendations.
What Are DOGP's Weaknesses?
Negative P/E ratio and profit margin indicate financial challenges.
- Limited operating history and small employee base.
- Dependence on evolving regulatory landscape.
- Intense competition from established telemedicine providers.
What Could Drive DOGP Stock Higher?
Potential expansion of PrestoDoctor into new states legalizing medical marijuana.
- Launch of branded men's and women's fashion apparel through www.cbds.com.
- Increasing acceptance and legalization of medical marijuana in the United States.
- Growing demand for telemedicine services for convenient healthcare access.
What Are the Key Risks for DOGP?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Changes in regulations and legal restrictions on cannabis could negatively impact operations.
- Competition from larger and more established telemedicine companies.
- Negative P/E ratio and profit margin indicate financial instability.
- Limited access to capital and funding opportunities.
- High price volatility and illiquidity due to OTC listing.
What Are the Growth Opportunities for DOGP?
- Expansion into New States: Dogecoin Cash, Inc. has the opportunity to expand its PrestoDoctor platform into new states as medical marijuana legalization progresses. Each new state represents a potential market for its telemedicine services. The timeline for this expansion depends on the legislative landscape in each state, but successful entry into key markets could significantly boost revenue and market share. This expansion would require navigating different regulatory environments and tailoring its services to meet local requirements.
- Development of New Cannabis-Related Products: The company's development of lozenges, balms, and creams represents a growth opportunity. By introducing innovative and targeted products, Dogecoin Cash, Inc. can attract new customers and increase revenue streams. The market for cannabis-infused products is expanding, with consumers seeking various forms of consumption and therapeutic benefits. The timeline for product development and launch depends on research, formulation, and regulatory approvals.
- Expansion of the www.cbds.com Website: Dogecoin Cash, Inc.'s plan to offer branded men's and women's fashion apparel through its www.cbds.com website represents a diversification strategy. By leveraging its existing online platform and customer base, the company can tap into the broader e-commerce market. The timeline for launching the fashion apparel line depends on sourcing suppliers, designing products, and setting up the online store. Success in this venture would require effective marketing and branding efforts.
- Leveraging Intellectual Property for Edibles: Holding an intellectual property license for the manufacture of medical marijuana edibles provides Dogecoin Cash, Inc. with a unique opportunity. The edibles market is a significant segment of the cannabis industry, offering a discreet and convenient consumption method. By developing and marketing its own line of edibles, the company can capture a share of this growing market. The timeline for launching edibles depends on production capacity, regulatory compliance, and market demand.
- Partnerships with Cannabis Dispensaries: Dogecoin Cash, Inc. can explore partnerships with cannabis dispensaries to offer its PrestoDoctor services to their customers. By integrating its telemedicine platform with dispensaries' online or in-store operations, the company can reach a wider audience and streamline the process of obtaining medical marijuana recommendations. The timeline for establishing partnerships depends on negotiations, integration efforts, and mutual benefits.
What Threats Does DOGP Face?
- Changing regulations and legal restrictions on cannabis.
- Competition from larger and more established telemedicine companies.
- Potential for negative publicity or reputational damage.
- Economic downturn impacting consumer spending on cannabis products.
What Are DOGP's Competitive Advantages?
- First-mover advantage in providing telemedicine services for medical marijuana recommendations.
- Established PrestoDoctor platform with existing user base and physician network.
- Intellectual property license for the manufacture of medical marijuana edibles.
- Brand recognition within the cannabis telemedicine market.
What Does DOGP Do?
Dogecoin Cash, Inc., formerly known as Cannabis Sativa, Inc. until its name change in November 2024, is a healthcare information services company providing telemedicine solutions within the cannabis industry. The company's core offering is PrestoDoctor, an online platform that facilitates virtual consultations between patients and physicians for medical marijuana recommendations. Utilizing video conferencing technology, PrestoDoctor aims to streamline the process of obtaining medical marijuana cards for eligible individuals in the United States. Beyond its telemedicine platform, Dogecoin Cash, Inc. develops and markets cannabis-related products, including lozenges designed for relief, Recover, a deep penetrating healing balm, and Trauma Cream, a cannabinoid and THC-infused cream. The company also holds an intellectual property license for the manufacture of medical marijuana edibles. Additionally, Dogecoin Cash, Inc. intends to expand its offerings to include branded men's and women's fashion apparel sourced from suppliers, to be sold through its www.cbds.com website. Headquartered in Mesquite, Nevada, Dogecoin Cash, Inc. serves both the cannabidiol (CBD) and cannabis markets, navigating the complex regulatory environment surrounding these industries.
What Products and Services Does DOGP Offer?
- Provides telemedicine online referral services for customers desiring medical marijuana cards.
- Offers PrestoDoctor, an online telemedicine platform connecting patients with physicians.
- Facilitates video conferencing for medical marijuana recommendations.
- Develops lozenges for relief.
- Produces Recover, a deep penetrating healing balm for pain relief.
- Creates Trauma Cream, a cream infused with cannabinoids and THC.
- Intends to offer branded men's and women's fashion through www.cbds.com.
- Holds intellectual property license for manufacture of medical marijuana edibles.
How Does DOGP Make Money?
- Generates revenue through fees charged for telemedicine consultations on the PrestoDoctor platform.
- Sells cannabis-related products, including lozenges, balms, and creams, directly to consumers.
- Plans to generate revenue from the sale of branded fashion apparel through its online store.
- Potentially licenses its intellectual property for medical marijuana edibles to other companies.
What Industry Does DOGP Operate In?
Dogecoin Cash, Inc. operates within the rapidly evolving cannabis and telemedicine industries. The cannabis market is experiencing significant growth, driven by increasing legalization and acceptance of medical and recreational marijuana. Telemedicine is also expanding, fueled by technological advancements and a growing demand for remote healthcare services. Dogecoin Cash, Inc. aims to capitalize on the intersection of these two trends by providing online medical marijuana recommendations. However, the company faces competition from established telemedicine providers and other cannabis-focused businesses. The industry is also subject to complex and changing regulations, which can impact Dogecoin Cash, Inc.'s operations and growth prospects.
Who Are DOGP's Key Customers?
- Individuals seeking medical marijuana cards for various health conditions.
- Patients looking for convenient and accessible telemedicine consultations.
- Consumers interested in cannabis-related products for pain relief and other therapeutic benefits.
- Customers of cannabis dispensaries seeking medical marijuana recommendations.
- Individuals interested in purchasing branded fashion apparel through the company's online store.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 23 days ago
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 46 |
| 2026-08-26 | 46 |
| 2026-08-29 | 46 |
| 2026-09-01 | 46 |
| 2026-09-04 | 46 |
| 2026-09-07 | 46 |
| 2026-09-10 | 46 |
What changed?
The score has stayed at 46.
Over the same 18 days the stock moved +65.8%.
Insider Activity
The most recent 12 insider filings for Dogecoin Cash, Inc. break down as 12 sales and 0 purchases. On net that is roughly 1.3M shares disposed (about $39K), a signal worth weighing alongside the fundamentals.
Financial Health
Dogecoin Cash, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Dogecoin Cash, Inc. stands at 36.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -30.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.04 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -49.0%, the inverse of the P/E and a quick read on earnings relative to price.
Dogecoin Cash, Inc. (DOGP) Valuation Context
Valued at $2.13M, DOGP is classified as a micro-cap stock.
DOGP Revenue & Earnings Trend
In Q2 FY2026, DOGP generated $167K in top-line revenue, marking a sequential decrease of 13.7%. The company recorded a net loss of $127K, with diluted EPS of $-0.00. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, DOGP averaged $-0.00 in diluted EPS.
Company Profile
Dogecoin Cash, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Mesquite, US. The company is led by CEO David Tobias. DOGP has traded publicly since 2012.
DOGP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Established PrestoDoctor platform for telemedicine consultations.
- Intellectual property license for medical marijuana edibles.
- Focus on the growing cannabis and telemedicine industries.
- Direct-to-consumer approach for medical marijuana recommendations.
Bear Case
- Negative P/E ratio and profit margin indicate financial challenges.
- Limited operating history and small employee base.
- Dependence on evolving regulatory landscape.
- Intense competition from established telemedicine providers.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $166,511 | -$127,024 | -$0.0008 |
| Q1 FY2026 | $192,898 | -$197,892 | -$0.0012 |
| Q4 FY2025 | $171,406 | -$84,188 | -$0.0006 |
| Q3 FY2025 | $190,564 | -$173,099 | -$0.0011 |
Q2 FY2026 · filed 19 Aug 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
DOGP Latest News
No recent news available for DOGP.
DOGP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for DOGP.
Price Targets
Wall Street price target analysis for DOGP.
DOGP MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for DOGP; grades run from A+ (80-100) to F (below 30).
Leadership: David Tobias
CEO
David Tobias is the CEO of Dogecoin Cash, Inc. He is responsible for managing the company's overall strategy and operations. With a small team of 4 employees, Tobias oversees the development and execution of the company's business plan. His background includes experience in the cannabis and telemedicine industries. He is focused on expanding the PrestoDoctor platform and launching new products.
Track Record: Under David Tobias's leadership, Dogecoin Cash, Inc. has focused on expanding its PrestoDoctor platform and developing new cannabis-related products. He led the company through its name change from Cannabis Sativa, Inc. to Dogecoin Cash, Inc. in November 2024. His strategic decisions aim to capitalize on the growing cannabis and telemedicine markets.
DOGP OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Dogecoin Cash, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity may be sporadic. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Potential for fraud or manipulation due to lack of regulatory oversight.
- High price volatility and illiquidity.
- Limited access to capital and funding opportunities.
- Going concern risk due to financial challenges.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Monitor trading volume and price activity for signs of manipulation.
- Consult with a qualified financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Operation of the PrestoDoctor platform suggests a functional business.
- Development of cannabis-related products indicates ongoing product development efforts.
- Holding an intellectual property license for medical marijuana edibles provides some validation.
- Company has been in operation since before 2024, indicating some business history.
DOGP Healthcare Stock FAQ
Is DOGP a good stock?
Stock Expert AI does not rate DOGP buy, sell or hold. Dogecoin Cash, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about DOGP stock?
As of 2026-03-16, there is no available analyst coverage for Dogecoin Cash, Inc. (DOGP). The company's micro-cap status and OTC listing likely contribute to the lack of analyst attention. Investors should conduct their own thorough research and due diligence before considering an investment in DOGP.
What are the key factors to evaluate for DOGP?
Evaluate DOGP on fundamentals, analyst consensus, and risk factors. Dogecoin Cash, Inc. presents a high-risk, high-reward investment profile due to its focus on the evolving cannabis telemedicine market. Not financial advice.
How frequently does DOGP data refresh on this page?
DOGP's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven DOGP's recent stock price performance?
Dogecoin Cash, Inc. (DOGP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established PrestoDoctor platform for telemedicine consultations. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DOGP overvalued or undervalued right now?
Dogecoin Cash, Inc. (DOGP) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of DOGP?
Yes, most major brokerages offer fractional shares of Dogecoin Cash, Inc. (DOGP) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track DOGP's earnings and financial reports?
Dogecoin Cash, Inc. (DOGP) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for DOGP earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for OTC-listed companies.
- Financial data based on available information, which may be incomplete.